WO2003033007A1 - Compositions pharmaceutiques pour utilisation topique contenant des extraits de plantes medicinales avec actions antiphlogistiques et cicatrisantes - Google Patents
Compositions pharmaceutiques pour utilisation topique contenant des extraits de plantes medicinales avec actions antiphlogistiques et cicatrisantes Download PDFInfo
- Publication number
- WO2003033007A1 WO2003033007A1 PCT/EP2002/011357 EP0211357W WO03033007A1 WO 2003033007 A1 WO2003033007 A1 WO 2003033007A1 EP 0211357 W EP0211357 W EP 0211357W WO 03033007 A1 WO03033007 A1 WO 03033007A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- flowers
- malva
- althaea
- cicatrising
- pharmaceutical compositions
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 28
- 230000000699 topical effect Effects 0.000 title claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 8
- 230000000694 effects Effects 0.000 title description 16
- 230000001741 anti-phlogistic effect Effects 0.000 title description 5
- 239000002260 anti-inflammatory agent Substances 0.000 title description 3
- 244000042664 Matricaria chamomilla Species 0.000 claims abstract description 17
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims abstract description 17
- 240000000073 Achillea millefolium Species 0.000 claims abstract description 15
- 235000007754 Achillea millefolium Nutrition 0.000 claims abstract description 15
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims abstract description 10
- 235000013939 Malva Nutrition 0.000 claims abstract description 9
- 241000382417 Malva Species 0.000 claims abstract description 9
- 235000000060 Malva neglecta Nutrition 0.000 claims abstract description 9
- 235000006578 Althaea Nutrition 0.000 claims abstract description 8
- 244000130592 Hibiscus syriacus Species 0.000 claims abstract description 8
- 235000021525 Tilia platyphyllos Nutrition 0.000 claims abstract description 8
- 241001634539 Tilia platyphyllos Species 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 8
- 244000208874 Althaea officinalis Species 0.000 claims abstract description 7
- 235000006576 Althaea officinalis Nutrition 0.000 claims abstract description 7
- 240000002129 Malva sylvestris Species 0.000 claims abstract description 7
- 235000006770 Malva sylvestris Nutrition 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 4
- 231100000397 ulcer Toxicity 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 10
- 235000013311 vegetables Nutrition 0.000 claims description 10
- 238000002791 soaking Methods 0.000 claims description 7
- 239000012153 distilled water Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 206010040943 Skin Ulcer Diseases 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims 4
- 238000001704 evaporation Methods 0.000 claims 2
- 230000008020 evaporation Effects 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 208000035874 Excoriation Diseases 0.000 abstract description 8
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 7
- 208000025865 Ulcer Diseases 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 description 16
- DJDSLBVSSOQSLW-UHFFFAOYSA-N mono(2-ethylhexyl) phthalate Chemical compound CCCCC(CC)COC(=O)C1=CC=CC=C1C(O)=O DJDSLBVSSOQSLW-UHFFFAOYSA-N 0.000 description 14
- 210000003491 skin Anatomy 0.000 description 10
- 206010030113 Oedema Diseases 0.000 description 9
- 229920001525 carrageenan Polymers 0.000 description 9
- 235000010418 carrageenan Nutrition 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 229920002307 Dextran Polymers 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 230000003902 lesion Effects 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 206010040882 skin lesion Diseases 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 239000007791 liquid phase Substances 0.000 description 3
- 231100000019 skin ulcer Toxicity 0.000 description 3
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000004210 Pressure Ulcer Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- VCMGMSHEPQENPE-UHFFFAOYSA-N ketamine hydrochloride Chemical compound [Cl-].C=1C=CC=C(Cl)C=1C1([NH2+]C)CCCCC1=O VCMGMSHEPQENPE-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 231100000444 skin lesion Toxicity 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 1
- 239000001500 (2R)-6-methyl-2-[(1R)-4-methyl-1-cyclohex-3-enyl]hept-5-en-2-ol Substances 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- SYTRJRUSWMMZLV-UHFFFAOYSA-N 4-epimatricin Natural products C1=CC(O)(C)C2C1=C(C)CC(OC(C)=O)C1C2OC(=O)C1C SYTRJRUSWMMZLV-UHFFFAOYSA-N 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical compound CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 235000017945 Matricaria Nutrition 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- PMRJYBALQVLLSJ-UHFFFAOYSA-N chamazulene Natural products CCC1=CC2=C(C)CCC2=CC=C1 PMRJYBALQVLLSJ-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 230000037313 granulation tissue formation Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000010388 wound contraction Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
Definitions
- the present invention relates to pharmaceutical compositions for the topical use containing extracts of chamomile heads (Matricaria recutita), althaea roots (Althaea officinalis L.), malva flowers (Malva sylvestris), large- leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.), endowed with anti-inflammatory and cicatrising properties, for the treatment of skin inflammations and lesions.
- chamomile heads Matricaria recutita
- althaea roots Althaea officinalis L.
- malva flowers Malva sylvestris
- large- leaved lime flowers Tala Platyphyllos
- milfoil flowers Adchillea millefolium L.
- bedsores i.e. skin lesions which, due to reduced tissutal perfusion and loss of skin trophism and elasticity, tend to become chronic, is one of the most widespread consequences of protracted infirmity, especially in the elderly.
- the accumulation of free radicals reduces the tensile strength of the lesions by inhibiting hyaluronic acid, thus preventing tissutal reparative processes.
- Healing of skin lesions apparently occurs through a first "inflammatory" phase followed by a neo-angiogenesis and granulation tissue formation phase, with wound contraction and subsequent cicatrization and re-epithelization.
- Object of the present invention are pharmaceutical compositions for topical use containing extracts of chamomile heads (Matricaria recutit ⁇ ), althaea roots (Althaea officinalis L.), malva flowers (Malva sylvestris), large-leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.), useful for the treatment of skin infiammations and lesions.
- extracts of chamomile heads (Matricaria recutit ⁇ ), althaea roots (Althaea officinalis L.), malva flowers (Malva sylvestris), large-leaved lime flowers (Tillia Platyphyllos) and milfoil flowers (Achillea millefolium L.), useful for the treatment of skin infiammations and lesions.
- Said pharmaceutical compositions are preferably in the form of creams, gels, pastes or ointments, in which the extracts total content ranges from 10 to 40%.
- a preferred embodiment of the invention consists in a cream containing 20% extracts in Essex ® base cream (hereinafter referred to as BAR 2).
- BAR 2 The compositions can be prepared from extracts of each vegetable component, or from an extract obtainable from a mixture of all the vegetable components.
- the liquid phase is recovered by filtration, preferably under vacuum, and evaporated under reduced pressure at a temperature not higher than 35°C.
- 100 g vegetable components mixture is soaked in a 30/70 v/v distilled water/ethanol mixture, up to 1 litre final volume.
- BAR 1 The anti-inflammatory and cicatrising properties of the compositions containing the extracts of the invention were evaluated in rats by means of the following tests:
- Both the extract and the cream showed active, in fact topical application on rat skin reduced in a statistically significant way inflammation and oedema in the carrageenin and dextran oedema tests and enhanced the cicatrising action in the experimental excoriations and ulcers tests.
- BAR 1 extract was prepared soaking for 24 hours a mixture consisting of 100 g of each vegetable component, suitably ground, in distilled water and ethyl alcohol (30:70 v/v), to a final volume of one litre, stored in a tightly sealed dark vessel.
- the liquid phase was recovered by filtration under vacuum and the intense green liquid was evaporated under reduced pressure at a temperature of 30-35°C, to avoid degradation.
- Cream BAR 2 was prepared incorporating 20 g of BAR 1 extract in
- mice Male Sprague-Dawley rats, (about 120-150 g weight) purchased from Harlan Italy (Udine, Italy), housed in single cages, under controlled temperature and humidity (22 ⁇ 1°C, 60% humidity).
- Treatments BAR 1 extract or Cream BAR 2 were applied on the area to be treated.
- a suspension of carrageenin (0.1 ml, 1% in normal saline) was administered to one of the rats hind paws.
- leg volume was evaluated with a pletismometer (Basile, Varese), prior to carrageenin injection (reference value) and after 2, 4, 8, 24 hours.
- the values reported in the table refer to percentage increases in the paw volume compared with the reference value.
- BAR 1 extract was applied to the rat paw immediately after carrageenin injection and after each evaluation. Dextran oedema test
- a 5% dextran solution (0.1 ml) in saline was administered to one of the rats hind paws.
- leg volume was evaluated with a pletismometer (Basile, Varese), prior to dextran injection (reference value) and after 2, 4, 8, 24 hours.
- the values reported in the table refer to percentage increases in the leg volume compared with the reference value.
- BAR 1 extract was applied to the rat paw immediately after carrageenin injection and after each evaluation.
- Ketavet (Gellini pharmaceutical), then shaved on the back so as to define a 1.5 cm diameter circular area. After that, the skin was scarified with a scalpel, then Essex ® base cream was applied to control animals, whereas BAR 2 was applied to the treated ones.
- Table 1 shows that in a 24 hours evaluation BAR 1 reduces carrageenin-induced oedema in a statistically significant way compared with controls, at any surveying time.
- BAR 1 significantly reduces (table 2) the percentage of paw volume increase induced by dextran, and is particularly active between 4-6 hours.
- Table N°l Effect induced by BAR 1 on carrageenin oedema in rats
- Table 3 shows that BAR 2 accelerates cutaneous reparative processes subsequent to excoriations. Values observed at 48, 72 and 96 hours from excoriations are in fact much higher in treated animals than in controls. In particular, the effect is statistically significant at 72 and 96 hours.
- the results show that BAR 1 extract and the topical pharmaceutical compositions containing it have excellent antiphlogistic and cicatrising activities. Therefore, the pharmaceutical compositions containing the extracts of the invention, in particular BAR 1 extract, can be used in the treatment of skin conditions wherein reduction of inflammation and improvement of tissue repair processes are required, in particular for healing bedsores.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
Les extraits de pétales de camomille (Matricaria recutita), de racines de guimauve (Althaea officinalis L.), de fleurs de mauve (Malva sylvestris), de fleurs de lime à larges feuilles (Tillia Platyphyllos) et de fleurs de myriophylle (Achillea millefolium L.) sont dotés de propriétés anti-inflammatoires et cicatrisantes. Ils peuvent par conséquent être utilisés pour la préparation de médicaments topiques destinés au traitement des inflammations de la peau, des excoriations et des ulcères.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2001MI002142A ITMI20012142A1 (it) | 2001-10-17 | 2001-10-17 | Composizioni farmaceutiche per uso topico contenenti estratti di erbemedicinali ad attivita' antilogistica e cicatrizzante |
| ITMI2001A002142 | 2001-10-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2003033007A1 true WO2003033007A1 (fr) | 2003-04-24 |
Family
ID=11448511
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2002/011357 WO2003033007A1 (fr) | 2001-10-17 | 2002-10-10 | Compositions pharmaceutiques pour utilisation topique contenant des extraits de plantes medicinales avec actions antiphlogistiques et cicatrisantes |
Country Status (2)
| Country | Link |
|---|---|
| IT (1) | ITMI20012142A1 (fr) |
| WO (1) | WO2003033007A1 (fr) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006047470A3 (fr) * | 2004-10-26 | 2006-06-22 | Johnson & Johnson Consumer | Compositions contenant un extrait de malva sylvestris et utilisation de ces compositions sur des tissus muqueux |
| WO2007112204A3 (fr) * | 2006-03-23 | 2007-11-29 | Johnson & Johnson Consumer | Extraits contenant des compositions pouvant être ingérées |
| EP1967187A1 (fr) | 2007-03-06 | 2008-09-10 | Rachid Ennamany | Composition à base de rutine et de L-lysine |
| JP2008285424A (ja) * | 2007-05-15 | 2008-11-27 | Maruzen Pharmaceut Co Ltd | プロフィラグリン産生促進剤、フィラグリン産生促進剤及びシクロオキシゲナーゼ−２活性阻害剤 |
| WO2008146009A1 (fr) | 2007-06-01 | 2008-12-04 | Insignion Holdings Limited | Extrait végétal et son utilisation thérapeutique |
| KR100967018B1 (ko) | 2003-04-09 | 2010-06-30 | 애경산업(주) | 식물 추출물을 함유한 피부 미백 화장료 |
| US20150265668A1 (en) * | 2011-05-16 | 2015-09-24 | Haus Bioceuticals, Inc. | Compositions of herbal formulations and uses thereof |
| EP3150213A1 (fr) | 2015-10-01 | 2017-04-05 | Braerg - Groupo Brasileiro de Pesquisas Especializadas Ltda | Une composition médicale ayant un effet antibiotique, anti-inflammatoire et cicatrisant les plaies |
| ITUB20160058A1 (it) * | 2016-01-19 | 2017-07-19 | Farm S R L C U S | Composizione di un preparato per il trattamento delle punture di insetto con attivita’ vasocostrittiva, lenitiva, disinfiammante e disarrossante |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4933177A (en) * | 1981-02-27 | 1990-06-12 | Societe Anonyme Dite: L'oreal | Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent |
| RU1561262C (ru) * | 1980-10-13 | 1994-10-30 | Научно-производственное объединение "ВНИИ лекарственых и ароматических растений" | Состав, обладающий противовоспалительной активностью "ротокан |
| WO1998034591A1 (fr) * | 1997-02-11 | 1998-08-13 | The Procter & Gamble Company | Compositions pour reduire l'hyperpigmentation de la peau |
| US5876703A (en) * | 1994-12-02 | 1999-03-02 | Kao Corporation | Flavanonol derivatives and hair-nourishing, hair-growing compositions containing the derivatives |
-
2001
- 2001-10-17 IT IT2001MI002142A patent/ITMI20012142A1/it unknown
-
2002
- 2002-10-10 WO PCT/EP2002/011357 patent/WO2003033007A1/fr not_active Application Discontinuation
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU1561262C (ru) * | 1980-10-13 | 1994-10-30 | Научно-производственное объединение "ВНИИ лекарственых и ароматических растений" | Состав, обладающий противовоспалительной активностью "ротокан |
| US4933177A (en) * | 1981-02-27 | 1990-06-12 | Societe Anonyme Dite: L'oreal | Cosmetic compositions for the treatment of the hair and skin contain in the form of a powder particles resulting from the pulverization of at least one plant substance and a cohesion agent |
| US5876703A (en) * | 1994-12-02 | 1999-03-02 | Kao Corporation | Flavanonol derivatives and hair-nourishing, hair-growing compositions containing the derivatives |
| WO1998034591A1 (fr) * | 1997-02-11 | 1998-08-13 | The Procter & Gamble Company | Compositions pour reduire l'hyperpigmentation de la peau |
Non-Patent Citations (4)
| Title |
|---|
| AERTGEERTS, J.: "Résultats obtenus avec le Kamillosan(R), un extrait standardisée de camomille, en pratique dermatologique", ARS MEDICI, vol. 39, 1984, pages 65 - 68, XP001122220 * |
| DATABASE WPI Section Ch Week 199523, Derwent World Patents Index; Class B04, AN 1995-176551, XP002228065 * |
| DELLA LOGGIA R ET AL: "THE ROLE OF FLAVONOIDS IN THE ANTIINFLAMMATORY ACTIVITY OF CHAMOMILLA-RECUTITA", PROGRESS IN CLINICAL AND BIOLOGICAL RESEARCH, 1986, pages 481 - 484, XP001122218, ISSN: 0361-7742 * |
| TUBARO A ET AL: "EVALUATION OF ANTIINFLAMMATORY ACTIVITY OF A CHAMOMILE CHAMOMILLA-RECUTITA EXTRACT AFTER TOPICAL APPLICATION", PLANTA MEDICA, vol. 51, no. 4, 1984, pages 359, XP009004098, ISSN: 0032-0943 * |
Cited By (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100967018B1 (ko) | 2003-04-09 | 2010-06-30 | 애경산업(주) | 식물 추출물을 함유한 피부 미백 화장료 |
| WO2006047470A3 (fr) * | 2004-10-26 | 2006-06-22 | Johnson & Johnson Consumer | Compositions contenant un extrait de malva sylvestris et utilisation de ces compositions sur des tissus muqueux |
| US7754248B2 (en) | 2004-10-26 | 2010-07-13 | Johnson & Johnson Consumer Companies, Inc. | Ingestible compositions containing extracts |
| WO2007112204A3 (fr) * | 2006-03-23 | 2007-11-29 | Johnson & Johnson Consumer | Extraits contenant des compositions pouvant être ingérées |
| EP1967187A1 (fr) | 2007-03-06 | 2008-09-10 | Rachid Ennamany | Composition à base de rutine et de L-lysine |
| JP2008285424A (ja) * | 2007-05-15 | 2008-11-27 | Maruzen Pharmaceut Co Ltd | プロフィラグリン産生促進剤、フィラグリン産生促進剤及びシクロオキシゲナーゼ−２活性阻害剤 |
| CN101687001A (zh) * | 2007-06-01 | 2010-03-31 | 因塞尼昂控股有限公司 | 植物提取物及其治疗用途 |
| WO2008146009A1 (fr) | 2007-06-01 | 2008-12-04 | Insignion Holdings Limited | Extrait végétal et son utilisation thérapeutique |
| AU2008256536B2 (en) * | 2007-06-01 | 2011-04-21 | Insignion Holdings Limited | Plant extract and its therapeutic use |
| RU2438692C2 (ru) * | 2007-06-01 | 2012-01-10 | Инсайнион Холдингз Лимитед | Растительный экстракт и его терапевтическое применение |
| US8591966B2 (en) | 2007-06-01 | 2013-11-26 | Insignion Holdings Limited | Composition containing oils of chamomile flower and black cumin with reduced endotoxins |
| US20150265668A1 (en) * | 2011-05-16 | 2015-09-24 | Haus Bioceuticals, Inc. | Compositions of herbal formulations and uses thereof |
| US9889174B2 (en) * | 2011-05-16 | 2018-02-13 | Haus Bioceuticals, Inc. | Compositions of herbal formulations and uses thereof |
| EP3150213A1 (fr) | 2015-10-01 | 2017-04-05 | Braerg - Groupo Brasileiro de Pesquisas Especializadas Ltda | Une composition médicale ayant un effet antibiotique, anti-inflammatoire et cicatrisant les plaies |
| ITUB20160058A1 (it) * | 2016-01-19 | 2017-07-19 | Farm S R L C U S | Composizione di un preparato per il trattamento delle punture di insetto con attivita’ vasocostrittiva, lenitiva, disinfiammante e disarrossante |
Also Published As
| Publication number | Publication date |
|---|---|
| ITMI20012142A1 (it) | 2003-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Raina et al. | Medicinal plants and their role in wound healing | |
| Agyare et al. | African medicinal plants with wound healing properties | |
| Abdulla et al. | Role of Ficus deltoidea extract in the enhancement of wound healing in experimental rats | |
| Vaisakh et al. | The invasive weed with healing properties: A review on Chromolaena odorata | |
| US20190008906A1 (en) | Compositions for management of wounds, skin diseases, dehydration, chronic diseases, and respiratory diseases | |
| Nasiry et al. | Anti-inflammatory and wound-healing potential of golden chanterelle mushroom, Cantharellus cibarius (Agaricomycetes) | |
| EP2008661A2 (fr) | Formule à base de aloès de souci et de centellae | |
| KR101229992B1 (ko) | 상처 치료용 약초 제제 | |
| CN105232411A (zh) | 一种天然植物防腐剂组合物及其在化妆品中的应用 | |
| Mathew et al. | Evaluation of anti-inflammatory and wound healing activity of Gentiana lutea rhizome extracts in animals | |
| Mishra et al. | Efficacy of hydrogel containing rutin in wound healing | |
| WO2003033007A1 (fr) | Compositions pharmaceutiques pour utilisation topique contenant des extraits de plantes medicinales avec actions antiphlogistiques et cicatrisantes | |
| EP3247211A1 (fr) | Dispersion microbicide huile dans eau | |
| Adiele et al. | Wound healing effect of methanolic leaf extract of Napoleona vogelii (Family: Lecythidaceae) in rats | |
| DE102021200975B4 (de) | Biologisch-basierte Wundverschlusszubereitung | |
| Herman et al. | Herbal Products in Postsurgical Wound Healing–Incision, Excision and Dead Space Wound Models | |
| US6699512B2 (en) | Hypericum perforatum l. oleoresin, procedure for obtaining it and uses of it | |
| Bist et al. | Embelia ribes: A valuable medicinal plant | |
| Gastaldi et al. | Solidago chilensis Meyen (Asteraceae), a medicinal plant from South America. A comprehensive review: ethnomedicinal uses, phytochemistry and bioactivity | |
| Chowdhary et al. | Wound healing activity of aqueous extracts of Ficus religiosa and Ficus benghalensis leaves in rats | |
| US7344737B2 (en) | Herbal composition for cuts, burns and wounds | |
| Ullah et al. | Medicinal benefits of lemon balm (Melissa officinalis) for human health | |
| Bairy | Wound healing potentials of plant products | |
| KR20210077365A (ko) | 토란 생물전환 추출물을 포함하는 화장료 조성물 및 이의 제조방법 | |
| CN115844777A (zh) | 一种含植物提取物的止痒抗菌消炎组合物及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: JP |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |